celecoxib has been researched along with thioacetamide in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Gao, JH; Huang, ZY; Liu, ZX; Lu, YY; Tang, CW; Tong, H; Wen, SL; Yang, WJ | 2 |
| Feng, S; Gao, JH; Huang, ZY; Liu, R; Lu, YY; Tang, CW; Tang, SH; Tang, YM; Tong, H; Wen, SL; Xie, HQ; Yang, JH; Yang, WJ | 1 |
| Gao, JH; Su, W; Tai, Y; Tang, CW; Tang, SH; Tuo, BG; Ye, YT; Zhao, C | 1 |
| Gan, C; Gao, J; Huang, Z; Jia, X; Jiang, J; Liu, R; Ma, X; Su, W; Tai, Y; Tang, C; Tang, S; Wu, H; Ye, Y; Zhang, L; Zhao, C | 1 |
6 other study(ies) available for celecoxib and thioacetamide
| Article | Year |
|---|---|
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Celecoxib ameliorates portal hypertension of the cirrhotic rats through the dual inhibitory effects on the intrahepatic fibrosis and angiogenesis.
Topics: Angiogenesis Inhibitors; Animals; Celecoxib; Disease Models, Animal; Hypertension, Portal; Kidney; Liver Cirrhosis; Male; Neovascularization, Pathologic; Pyrazoles; Rats; Rats, Sprague-Dawley; Signal Transduction; Sulfonamides; Thioacetamide | 2013 |
Celecoxib attenuates hepatic cirrhosis through inhibition of epithelial-to-mesenchymal transition of hepatocytes.
Topics: Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Down-Regulation; Epithelial-Mesenchymal Transition; Hepatocytes; Liver Cirrhosis; Liver Cirrhosis, Experimental; Pyrazoles; Rats, Sprague-Dawley; Signal Transduction; Smad Proteins; Sulfonamides; Thioacetamide; Transforming Growth Factor beta1 | 2014 |
Celecoxib and octreotide synergistically ameliorate portal hypertension via inhibition of angiogenesis in cirrhotic rats.
Topics: Angiogenesis Inhibitors; Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Synergism; Hypertension, Portal; Hypoxia-Inducible Factor 1, alpha Subunit; Liver; Liver Cirrhosis, Experimental; MAP Kinase Signaling System; Neovascularization, Pathologic; Octreotide; Portal Pressure; Promoter Regions, Genetic; Rats; Rats, Sprague-Dawley; Signal Transduction; Thioacetamide; Vascular Endothelial Growth Factor A | 2016 |
Celecoxib attenuates hepatocyte apoptosis by inhibiting endoplasmic reticulum stress in thioacetamide-induced cirrhotic rats.
Topics: Animals; Apoptosis; Celecoxib; Endoplasmic Reticulum Stress; Endoribonucleases; Hepatocytes; Liver Cirrhosis; Male; Protein Serine-Threonine Kinases; Rats; Rats, Sprague-Dawley; Thioacetamide | 2020 |
Celecoxib ameliorates liver cirrhosis via reducing inflammation and oxidative stress along spleen-liver axis in rats.
Topics: Animals; Apoptosis; Celecoxib; China; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Hepatic Stellate Cells; Hepatocytes; Inflammation; Liver; Liver Cirrhosis; Liver Cirrhosis, Experimental; Male; Oxidative Stress; Rats; Rats, Sprague-Dawley; Signal Transduction; Spleen; Splenomegaly; Thioacetamide | 2021 |